Collin Blakely: Neoadjuvant Osimertinib for the Treatment of Non–Small Cell Lung Cancer
Collin Blakely, Associate Professor of Thoracic Medical Oncology and Clinical Scientist at UCSF, shared a post on X about his recent paper commenting:
“Pleased to report the results of our clinical trial: Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung.
Thank you to all of the patients who participated.
Also thank you to our fantastic research and clinical teams at UCSF Cancer and my co-investigators and collaborators”
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study published in ASCO Publications.
Authors: Collin M. Blakely, Anatoly Urisman, Matthew A. Gubens, Claire K. Mulvey, Greg M.Allen, Stephen C. Shiboski, Julia K. Rotow, Turja Chakrabarti, D. Lucas Kerr, Jacqueline V. Aredo, Bianca Bacaltos, Megan Gee, LisaTan, Kirk D. Jones, W. Patrick Devine, Robert C.Doebele, Dara L. Aisner, Tejas Patil, Erin L. Schenk, Trever G. Bivona, Jonathan W. Riess, Melissa Coleman, Johannes R. Kratz, David M. Jablons.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023